Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A malignant germ cell tumor characterized by the presence of at least two different germ cell components. The different germ cell components include choriocarcinoma, embryonal carcinoma, yolk sac tumor, teratoma, and seminoma. It occurs in the ovary, testis, and extragonadal sites including central nervous system and mediastinum.
Biomarker and diagnostic research for mixed germ cell tumor has been reported in the published literature.
4 clinical trials registered, 2 recruiting. Interventions under study include drug therapy, procedural interventions, other interventions, and biologic therapy. Pipeline includes 1 PHASE3, 2 PHASE2. Research is primarily sponsored by academic and government institutions.
173 publications have been identified in PubMed for mixed germ cell tumor. Research spans Case Report / Case Series (34%), Basic Science / Preclinical (21%), and Review / Meta-Analysis (20%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 50 |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 5:57 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
34%
Laboratory research | 31 | 21% |
Research summaries | 30 | 20% |
Clinical study results | 13 | 9% |
Disease patterns and progression | 12 | 8% |
New treatment approaches | 12 | 8% |
Testing and diagnosis research | 1 | 1% |
Di Costanzo F (2026). [PMID: 40494333](https://pubmed.ncbi.nlm.nih.gov/40494333/). *Oncol Res Treat*. [Review / Meta-Analysis]
Noto Y (2026). [PMID: 41736172](https://pubmed.ncbi.nlm.nih.gov/41736172/). *Pathol Int*. [Case Report / Case Series]
Dey S (2026). [PMID: 42210622](https://pubmed.ncbi.nlm.nih.gov/42210622/). *Cancer Med*. [Clinical Trial Publication]
Desar S (2026). [PMID: 41622830](https://pubmed.ncbi.nlm.nih.gov/41622830/). *Adv Anat Pathol*. [Review / Meta-Analysis]
Partenope C (2026). [PMID: 42238235](https://pubmed.ncbi.nlm.nih.gov/42238235/). *Front Endocrinol (Lausanne)*. [Epidemiology / Natural History]
Tanguy R (2026). [PMID: 42115465](https://pubmed.ncbi.nlm.nih.gov/42115465/). *Adv Tech Stand Neurosurg*. [Review / Meta-Analysis]
Omameuda T (2026). [PMID: 41991407](https://pubmed.ncbi.nlm.nih.gov/41991407/). *Transplant Proc*. [Case Report / Case Series]
Mubeen B (2026). [PMID: 41958792](https://pubmed.ncbi.nlm.nih.gov/41958792/). *J Indian Assoc Pediatr Surg*. [Case Report / Case Series]
Yuan Q (2026). [PMID: 41810207](https://pubmed.ncbi.nlm.nih.gov/41810207/). *Transl Pediatr*. [Case Report / Case Series]
Yang J (2026). [PMID: 41924289](https://pubmed.ncbi.nlm.nih.gov/41924289/). *Front Pediatr*. [Case Report / Case Series]